Genco Shipping & Trading has extended its shareholder rights plan by another year, pushing the poison pill's final expiry from September 30, 2026 to September 30, 2027 — a defensive posture that outlasts Diana Shipping's collapsed nine-month pursuit of the US-listed bulker owner.

The company revealed the extension on Friday. The board said it based the decision on the advisory shareholder vote at June's annual meeting, investor feedback and its continuing review of the arrangement.

Genco did not simply roll the plan forward. It also loosened several provisions governing what counts as a qualifying takeover offer, making the mechanics of any future bid somewhat more workable for an acquirer.

The period used to determine the minimum qualifying offer price has been cut from 24 months to 12 months before an offer is launched. The price test will also no longer continue running once the offer has been made.

The board's windows for considering a qualifying offer and for calling a special shareholder meeting have switched from 90 business days to 90 calendar days — effectively shortening both periods in real time. An offeror will also be permitted to withdraw its bid if a continuing material adverse effect occurs. The rest of the rights plan stands unchanged.

The extension closes out a turbulent chapter for the dry bulk owner. Genco adopted the original one-year poison pill in October 2025 after Diana Shipping built a stake of almost 15% in the company — a position large enough to trigger boardroom alarm and, ultimately, a full takeover and proxy battle that grew increasingly bitter.

Shareholders backed the rights plan at the June annual meeting, giving the board a mandate for the defence even as Diana pressed its case.

That battle is now over. Diana pulled its takeover proposal in August after the two owners failed to bridge a wide valuation gap. Since then, the Greek owner has been unwinding its position rapidly: by early September, its holding had fallen to about 9.5%, after disposals worth roughly $56.8m.

For Genco's remaining shareholders, the calculus is straightforward. The board has kept its core anti-takeover instrument intact while trimming the provisions that critics of poison pills most often attack — the long look-back period for pricing a qualifying offer and the open-ended price test. That balance suggests management wants flexibility against any renewed accumulation of stock rather than a permanent barrier to a sale.

The softer terms also matter for any future bidder. A 12-month measurement window and a 90-calendar-day decision clock shorten the path a would-be acquirer must navigate to put a qualifying offer in front of shareholders, and the withdrawal right on a material adverse effect reduces the downside risk of tabling a bid that market conditions turn against.

Diana's retreat removes the most immediate threat, but it does not rule out another approach — from Diana at a lower exit, once its stake sale is complete, or from a third party attracted by a US-listed dry bulk platform trading below the valuation Diana was prepared to pay. The extension to September 2027 gives Genco's board three more years of cover in that scenario.

Watch the September 2026 annual meeting cycle for the next signal: if no fresh stake builds by then, the board faces another advisory vote on a plan it has now twice adjusted in response to investor feedback, and the trajectory of those votes will indicate whether shareholders still see the defence as protection or as an obstacle to value.